

REMARKS/ARGUMENTS

Claims 29-30 are cancelled. Claims 8-9, 25, and 27-28 have been amended.

Rejections under 35 U.S.C. § 101

The Examiner has rejected claim 9 as being directed to non-statutory subject matter. This rejection has been considered and claim 9 has been amended to specify that the cell as claimed is "isolated", as suggested by the Examiner.

Reconsideration and withdrawal of this rejection is therefore respectfully requested.

Rejections under 35 U.S.C. § 102

The Examiner has rejected claim 8 under 35 U.S.C. § 102(a) as being anticipated by Slack et al.. This rejection has been considered and claim 8 has been amended to specify that the vector is "consisting of a backbone sequence and an insert sequence, wherein said insert sequence is consisting of a sequence encoding the oligonucleotide inhibitor as set forth in SEQ ID NO:12". The term "vector backbone" referring to the sequence of a recombinant vector that is not the insert is well known in the art (see Annex 1 attached hereto). Thus, the invention as claimed would be a vector backbone with the insert nucleotide sequence being solely SEQ ID NO:12. No new matter is being introduced herewith and the vector backbone and insert sequence is known to one skilled in the art of recombinant DNA as common general knowledge.

Reconsideration and withdrawal of this rejection is therefore respectfully requested.

Rejection under 35 U.S.C. § 112, first paragraph

The Examiner has rejected former claims 25, 27-28, and 30-31 as failing to comply with the enablement requirement. This rejection has been considered and the claims have been amended to be restricted to lung and colorectal cancer.

Reconsideration and withdrawal of this rejection is therefore respectfully requested.

In view of the foregoing, the application is respectfully submitted to be in condition for allowance, and prompt, favorable action thereon is earnestly solicited.

Applicant respectfully requests that a timely Notice of Allowance be issued in this case.

If there are any questions regarding this amendment or the application in general, the Examiner is respectfully requested to telephone the undersigned at (514) 871-2929 so that such questions can be expeditiously resolved.

FEE AUTHORIZATION

Should any fees associated with the submission be required, the Commissioner is authorized to charge such deficiencies to our Deposit Account No. 02-2095. Any overpayments should be credited to said Deposit Account.

Respectfully submitted,

Moshe Szyf et al.

By: 
France Côté
Reg./No. 37,037
Tel: 514-871-2929